SCHEMBL6479660

SCHEMBL6479660

O=C(NO)[C@H]1[C@@H]2CC[C@@H](C2)N1S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
PSEN1 P49768 2/20 0.44
PSEN2 P49810 2/20 0.44
APH1B Q8WW43 2/20 0.44
NCSTN Q92542 2/20 0.44
APH1A Q96BI3 2/20 0.44
PSENEN Q9NZ42 2/20 0.44
MMP1 P03956 2/20 0.44
ACHE P22303 1/20 0.44
ADAM17 P78536 1/20 0.44
CYP3A4 P08684 2/20 0.43
TRPA1 O75762 2/20 0.42
MMP8 P22894 3/20 0.42
MMP3 P08254 2/20 0.42
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42
AKR1C3 P42330 1/20 0.42
CNR1 P21554 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14574740 1.00 MEN1 (0.45) MEN1KMT2APSEN1PSEN2APH1B
SCHEMBL14574788 0.88 TRPA1 (0.53) KMT2AMMP1ADAM17TRPA1MMP3
SCHEMBL14575038 0.88 ITGB1 (0.46) MMP1ACHEADAM17MMP2MMP9
SCHEMBL6490527 0.88 TRPA1 (0.53) KMT2AMMP1ADAM17TRPA1MMP3
SCHEMBL14574787 0.87 ALDH1A1 (0.50) MEN1KMT2AMMP1ADAM17TRPA1
SCHEMBL6479973 0.87 ALDH1A1 (0.50) MEN1KMT2AMMP1ADAM17TRPA1
SCHEMBL14575007 0.84 ALDH1A1 (0.61) MMP1ADAM17MMP8MMP3MMP2
SCHEMBL4032000 0.84 ALDH1A1 (0.61) MMP1ADAM17MMP8MMP3MMP2
SCHEMBL6493434 0.84 ALDH1A1 (0.61) MMP1ADAM17MMP8MMP3MMP2
SCHEMBL6491614 0.84 ALDH1A1 (0.61) MMP1ADAM17MMP8MMP3MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176217-B2 Azabicyclo compound matrix metalloprotease inhibitor and skin preparation SHISEIDO CO., LTD. (JP) 2007-02-13 US disclosed
US-20050009808-A1 Azabicyclo compound matrix metalloprotease inibitor and skin preparation SHISEIDO CO., LTD. (JP) 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009808-A1 Azabicyclo compound matrix metalloprotease inibitor and skin preparation MMP1, MMP16, MMP9 MEN1 2289/4885KMT2A 927/4885PSEN1 2335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.